🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

TG Therapeutics, Inc. TGTX R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.tgtherapeutics.com
Company Profile ↓
$55.98
+100.88% 1Y
Mkt Cap$8.57B
P/E20.43
P/B12.10
52W High$59.06
52W Low$26.94
Book Value$4.11
EPS (TTM)$2.74

Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 69.0%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 151.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 20.4, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 55.2%.

Recent Developments

  • Dec 2025 Revenue of $616.29M (+87.3% YoY); net profit $447.18M.
  • Trailing 12 Months Year-on-year growth — revenue +70.3%, earnings -70.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 151.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:151.70%
1 Year:70.30%

Compounded Profit Growth

5 Years:-
1 Year:-70.60%

Stock Price Performance

1 Year:+100.88%
6 Months:+91.27%
3 Months:+39.40%
1 Month:+12.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 90% of range
$26.94 $59.06
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.69 · Neutral
Price Performance
1M+12.99%
3M+39.40%
6M+91.27%
1Y+100.88%
Valuation vs Sector

P/E of 20.43 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 69.0%.
  • Excellent profit margin of 55.2%.
  • Compounding revenue at 151.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.43
Industry PE
25.17
Forward P/E
18.83
PEG Ratio
1.61
Book Value
$4.11
Price to Book
12.10
P/S
9.53
EV/EBITDA
53.44
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
151.70%
Profit 5Y
-
Revenue (YoY)
70.30%
Earnings (YoY)
-70.60%

Profitability & Returns

ROCE
13.56%
ROE
69.01%
ROA
42.06%
Profit Margin
55.22%
Op Margin
9.02%
Gross Margin
82.37%
EPS (Latest Qtr)
$0.05
EPS (TTM)
$2.74

Balance Sheet & Liquidity

Debt/Equity
1.29
Quick Ratio
3.29
Current Ratio
4.10
Debt
$753.56M
Total Assets
$1.64B
Current Assets
$630.76M
Working Capital
$477.00M

Ownership

Promoter Holding
7.47%
Chg in Prom Hold
-0.00%
FII / Inst Holding
74.15%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$8.57B
Total Revenue (TTM)
$799.54M
EBITDA
$136.43M
Free Cash Flow
$-24.99M
Operating Cash Flow
$-24.77M
Shares Outstanding
153.07M
Gross Margin
82.37%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TGTX TG Therapeutics, Inc. R2KR3KPHARMA 55.98 20.43 $8.57B 0.00% 13.56% 69.01% 151.70% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -------------------------2.02M594.00K94.00K7.80M16.07M165.81M63.47M73.47M83.88M120.86M141.15M161.71M192.57M204.92M240.34M
Cost of Revenue ----------------------------------15.54M18.94M28.09M38.14M33.51M-
Gross Profit ----------------------------------105.31M122.21M133.62M154.43M171.41M-
Operating Expenses ----------------------------------96.69M87.37M104.25M103.94M136.61M-
Operating Income -17.11M-13.83M--13.99M-16.02M-24.93M--27.67M-28.43M-31.59M--41.58M44.34M-34.33M--34.69M-35.54M-60.86M--50.24M-50.84M-85.72M-89.20M-77.49M-85.13M-66.87M-38.94M-34.96M-36.99M-44.67M114.78M-9.27M8.82M12.43M8.62M34.84M29.36M50.49M34.80M21.67M
EBITDA ----------------------------------12.28M37.70M32.69M51.69M28.11M-
Interest Expense ----------------------------------6.76M6.72M6.72M6.53M7.67M-
Pretax Income ----------------------------------5.47M30.92M25.91M45.09M20.36M-
Tax Provision ----------------------------------408.00K2.73M-364.99M22.06M586.00K-
Net Income -17.10M-13.66M-17.61M-13.85M-15.90M-24.83M-23.67M-27.73M-28.35M-31.54M-30.86M-41.53M-44.14M-33.95M-53.86M-35.16M-36.21M-61.93M-39.57M-------69.01M-40.51M-35.82M-39.23M-47.61M113.93M-10.71M6.88M3.88M5.06M28.19M390.89M23.04M19.78M7.78M
Diluted EPS -----------------------0.69-0.59-0.65-0.51-0.30-0.26-0.28-0.340.73-0.070.040.020.030.172.430.140.120.05
R&D Expense 11.26M11.57M-11.62M13.53M21.80M-22.68M26.71M27.15M-35.02M38.70M33.40M-32.38M32.87M57.98M-36.02M36.45M50.46M63.09M44.87M51.97M48.04M26.87M20.80M15.87M28.12M14.75M32.72M17.56M20.14M46.36M31.78M40.88M-48.40M95.34M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -----152.00K152.00K152.00K152.00K152.00K6.69M2.79M233.66M329.00M616.29M
Operating Income -881.97K-26.90M-22.97M-55.72M-63.18M-78.97M-118.71M-174.40M-169.06M-273.59M-344.77M-218.32M20.63M41.93M123.32M
Net Income -853.07K-18.07M-20.48M--------348.10M-223.81M12.67M23.38M447.18M
Diluted EPS ----------2.42-2.63-1.650.090.152.77
R&D Expense 327.28K21.03M13.66M40.09M47.71M69.23M102.53M159.39M154.18M165.90M222.58M125.35M76.19M94.29M160.22M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Nov 2011Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ---14.54M22.07M48.11M86.75M113.47M54.78M97.38M83.62M163.01M625.64M-193.57M329.59M577.69M1.06B
Current Assets --------------168.27M317.94M566.36M630.76M
Cash & Equivalents 0009.75M16.46M40.49M55.71M55.06M25.03M56.72M41.96M112.64M553.44M-102.30M92.93M179.89M79.15M
Inventory --------------039.82M110.46M125.59M
Receivables --------------051.09M129.19M305.63M
Total Liabilities ---4.90M6.52M8.06M6.65M11.90M18.91M30.39M59.58M124.40M106.29M-134.99M169.09M355.33M415.23M
Current Liabilities ---1.61M2.22M6.32M5.12M10.53M16.88M27.96M38.85M84.45M87.55M-53.20M53.72M90.68M153.76M
Long Term Debt ----------028.97M7.72M-71.14M100.12M244.43M245.65M
Total Debt --------------83.06M110.80M253.72M253.71M
Total Equity -0-9.62M15.55M40.05M80.10M101.57M35.87M66.99M24.04M38.62M519.35M-58.59M160.50M222.36M648.02M
Shares Outstanding --------------146.43M151.47M156.20M158.85M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -86.58K-5.27M-----93.76M-128.93M-132.81M-214.51M--176.17M-31.41M-40.52M-24.77M
Investing Cash Flow 10.39K8.99K-----8.21M1.18M-718.00K-24.51M--20.01M-50.65M-1.04M13.80M
Financing Cash Flow 9.82M21.72M----133.66M113.64M204.21M679.83M--391.00K72.70M128.53M-89.73M
Capital Expenditure -0-1.40K-5.68K-18.57K-42.22K-344.00K-2.00K-90.00K-131.00K-357.00K-401.00K-14.00K--45.00K-214.00K
Free Cash Flow -86.58K-5.28M-----93.76M-129.01M-132.94M-214.86M--176.18M-31.41M-40.56M-24.99M
Net Change in Cash ------------196.57M-9.36M86.97M-100.70M
Share Buybacks -84.54K149.80K00----------

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------
Operating Margin % ------51,953.3%-78,100.0%-114,736.8%-111,220.4%-179,996.1%-5,154.3%-7,839.0%8.8%12.7%20.0%
Net Margin % -----------5,204.1%-8,036.3%5.4%7.1%72.6%
ROE % -8.9%-116.2%-51.1%---------382.0%7.9%10.5%69.0%
ROCE % -6.8%-135.4%-54.9%-68.3%-61.4%-208.3%-171.0%-389.6%-215.2%-50.8%--155.5%7.5%8.6%13.6%

Shareholding Pattern

Insiders
7.47%
Institutions
74.15%
Public Float
80.13%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 14.41% 22.05M $1.19B
2 Vanguard Portfolio Management LLC 5.20% 7.96M $429.46M
3 State Street Corporation 5.09% 7.79M $419.92M
4 Vanguard Capital Management LLC 4.02% 6.15M $331.64M
5 Geode Capital Management, LLC 2.38% 3.64M $196.42M
6 Shaw D.E. & Co., Inc. 2.22% 3.40M $183.41M
7 Soleus Capital Management, L.P. 1.91% 2.93M $157.90M
8 Price (T.Rowe) Associates Inc 1.81% 2.77M $149.26M
9 ClearBridge Investments, LLC 1.73% 2.65M $142.92M
10 Congress Asset Management Co 1.70% 2.60M $140.22M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TGTX

Google News Mon, 07 Sep 2026

TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNQi15X2JuQlc3TGFQaEtid3FYR0tkZ1pJalU0c2dtTmZyODVKb0swYXFINlJ0X21xMU9iRXR0c0x6N0YtMDAwUWhGOTZZSjJqcFZaYzE4dE1PVC1lOUZQSUpYZzMwM1FFR2Q0THktMTJFSmFZVWtPWks5dnRXaDBIemtsMTBvdXRDTlU1VF…

Google News Fri, 21 Aug 2026

TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNbGVoT2lYT2d5ei1YU2tGQXZYTWgyS0dETWtOS0x3TWk1X1pZWTlyV2VvaHlGeG81SnRyaVZkV245TTc4YjFIQ3NJX2Q1T3dZc3BmLTN1bGM0UnlQcDd5TTVQYnl0bG1Qc3lFNzlKc3liZzdkT2ZaMElIUVVoamtVb3dUeEFhUVNKSVo3bU…

Google News Fri, 04 Sep 2026

TG Therapeutics (TGTX) Stock Looks Fairly Valued After A 4x Run - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPUjJlaVFDUktqOVRsNXNMQWd4bC1PVG15dnQxcHRMMVBhMXgyR1A0QWhqVU0tbHh1VEgwSzVGcldHZWZPM19obUNsWjl0Z0dvcVNMVnVZOWYwZTVXX1R4R1BMY2pOVzBpVVNHZ3RjLVRQTG9TeEJOci14alM3dkp3YWNta0czOFlSSllmYT…

Google News Mon, 24 Aug 2026

TGTX Stock Outperforms 95% of Stocks. Here's Why. - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPb0JoNzRXeENLYTUwRzRzQ0JUQjYwckgwbFNRNW81cDhzYkxFTndXTWljQUt0Rmt4dDMtNDZYVFAwWlItQ0pPOUYyQVdYa01tc2pZam95bi1UXzVNWHAtUGJKOHVOeWtiR05ZZ3Jvbm1EZm5qcGJvNTBQTElTYkhPOU9vTzg2ZFpHc19kLT…

Google News Mon, 07 Sep 2026

TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUnV6OEdJNzlqUGdqcExTVzRVaW9PR2dXTnRfeXp6OEZIbnhJT2g0Nk9ickRaVmNrZFZ0VGhrRDdhZm5PUDhESWEtS0ZDZUw3anVNNFFuLXRveTlVZVNtbWRPenAzUDh3OTBGM1ZaR2hITVZMTjdQVTJwTEVjWjNDYmE3S2tMSkFUSW5kVD…

Google News ue, 18 Aug 2026

TGTX Stock Rises 29% in 3 Months: Here's What You Should Know - qz.com

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE1PYlA2NGJ1MWFPT2VUZ2FuWExSZWdyaTd4TXlid3RQRmM5bU1mUUwwLWR5LWE5Smd6UnZuVXh1RHBULVhJT0RzX0o0TzRFR0F2X25NdVBHZWxoRUFZUlNfWk11ZlNCdWFkUjdrajJzUDVkbERtWDIyVkxVNXVjS0k?oc=5" target="_bla…

TGTX — Frequently Asked Questions

What is the current share price of TG Therapeutics, Inc. (TGTX)?

As of 2026-09-07 16:24 PDT, TG Therapeutics, Inc. (TGTX) trades at $55.98 on NasdaqCM. Its 52-week range is $26.94 to $59.06.

What is the market capitalisation of TGTX?

TG Therapeutics, Inc. (TGTX) has a market capitalisation of $8.57B on NasdaqCM.

What is the P/E ratio of TGTX?

TGTX trades at a trailing price-to-earnings (P/E) ratio of 20.43. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 12.10.

What is the return on equity (ROE) of TGTX?

TGTX has a return on equity (ROE) of 69.01%. Its return on capital employed (ROCE) is 13.56%.

Is TGTX a good stock to buy?

This page provides a data-driven analysis of TG Therapeutics, Inc. (TGTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space